2seventy bio, Inc.

Good day, and thank you for standing by. Welcome to the 270Bio Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jen Snyder, Head of Corporate Affairs. Please go ahead.

Thank you, Operator. This morning, 270Bio issued a press release providing a business update in addition to second quarter 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 270Bio.com. Speaking on the call today are Nick Leshley, Chief Kairos Officer, Chip Baird, Chief Financial Officer, and Steve Bernstein, Chief Medical Officer. Philip Gregory, Chief Scientific Officer, is also on the line for the Q&A section. As a reminder, today's discussion will include forward-looking statements related to 270-Bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, timelines, and expectations, and statements regarding our financial condition, expectations, and other future financial results, among others. Actual results may differ materially due to various risks, uncertainties, and other factors, including those described in the risk factors section of our most recent form 10-K and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. You are cautioned not to place any undue reliance on these forward-looking statements and, except as required by law, we undertake no obligation to update or revise any forward-looking statements. At this time, I would like to turn the call over to Nick Lashley. Nick?

Thanks, Jen. Good morning, everyone, and thank you for joining us as we discuss our second quarter 2023 results and business updates. We are now well into our second full year as 270Bios. executing on our mission of giving more time to people living with cancer through the transformative power of cell therapy. Since the creation of 270, our mission has always been dual-pronged, to deliver on the commercial potential of ABECMA and to leverage our translational engine to develop an innovative cell therapy pipeline. And in the first half of 2023, we've made important progress against these goals. With ABECMA, we continue to successfully deliver in the commercial setting to an extensive and growing number of people living with multiple myeloma who are in need of better treatment options. We recently hosted a myeloma patient and his wife at our all-hands meeting, reminding us the impact that ABECMA is having on patients and families. It was humbling, inspiring, and a deep reflection of our why. At the same time, we recognize we are in the midst of a rapidly evolving competitive environment, which is expected to impact the second half of ABECMA performance. Chip will comment more fully on ABECMA market dynamics. And I can say that we've spent a significant amount of time with the broader BMS team to hear not only their rationale for the long-term belief in the potential of APECMA, but also the month-to-month tactical in-line commercial strategy. It is both grounded in a strong understanding of the landscape and very well supported by internal resources, from the CEO to the sales rep, given their conviction to the cell therapy field. Overall, we're making significant short- and long-term investments with BMS to maximize the potential of this important therapy for patients. On the development side, we continue to apply our scientific knowledge and research engine to address some of the most pressing therapeutic challenges in oncology. We have a number of preclinical and clinical programs in liquid and solid tumors, and the common thread is that we're using layered cell therapy approaches to deliver potentially transformative impact for patients. One such program is Derek 33. Since the Grade 5 AE in June, the 270 and Seattle Children's team have conducted the root cause investigation and have developed potential amendments to the PLAT-08 protocol. This past Friday, Seattle Children's received the official notice of the FDA clinical hold. This was expected, and we need to hear more from the FDA in terms of their specific concerns and how it will impact the potential path forward for the program. Steve will provide more details later in this call. Our pipeline programs are stacked with innovation and represent multiple opportunities for us to make unincremental steps forward for patients with cancer. That said, we will also be clear-eyed and disciplined about these programs. And if a program is not clearing a very high bar, we will terminate and allocate capital elsewhere. I look forward to your questions, but for now, I'll hand it over to Chip to talk more about ABACMA and our Q2 results. Chip?